CA2717741C - Treatment of hearing and balance impairments with redox-active therapeutics - Google Patents

Treatment of hearing and balance impairments with redox-active therapeutics Download PDF

Info

Publication number
CA2717741C
CA2717741C CA2717741A CA2717741A CA2717741C CA 2717741 C CA2717741 C CA 2717741C CA 2717741 A CA2717741 A CA 2717741A CA 2717741 A CA2717741 A CA 2717741A CA 2717741 C CA2717741 C CA 2717741C
Authority
CA
Canada
Prior art keywords
alkyl
hydroxy
methyl
composition
redox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2717741A
Other languages
English (en)
French (fr)
Other versions
CA2717741A1 (en
Inventor
Guy M. Miller
Original Assignee
PTC Therapeutics Inc
Bioelectron Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc, Bioelectron Technology Corp filed Critical PTC Therapeutics Inc
Publication of CA2717741A1 publication Critical patent/CA2717741A1/en
Application granted granted Critical
Publication of CA2717741C publication Critical patent/CA2717741C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2717741A 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics Expired - Fee Related CA2717741C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6833008P 2008-03-05 2008-03-05
US61/068,330 2008-03-05
US19119808P 2008-09-05 2008-09-05
US61/191,198 2008-09-05
PCT/US2009/035996 WO2009111543A2 (en) 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics

Publications (2)

Publication Number Publication Date
CA2717741A1 CA2717741A1 (en) 2009-09-11
CA2717741C true CA2717741C (en) 2018-04-03

Family

ID=41056624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717741A Expired - Fee Related CA2717741C (en) 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics

Country Status (5)

Country Link
US (3) US20110046156A1 (https=)
EP (1) EP2262519A4 (https=)
JP (4) JP2011513420A (https=)
CA (1) CA2717741C (https=)
WO (1) WO2009111543A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) * 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2982382A1 (en) 2014-08-04 2016-02-10 Sensorion Compounds for preventing ototoxicity
AU2015364640B2 (en) * 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3767578B1 (en) 2015-04-16 2023-08-16 Honeywell International Inc. Multi-sensor input analysis for improved safety
ES3033538T3 (en) * 2015-10-08 2025-08-05 Khondrion Ip B V Novel compounds for treating mitochondrial disease
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101785455B1 (ko) * 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
KR102177610B1 (ko) * 2019-03-28 2020-11-11 단국대학교 천안캠퍼스 산학협력단 청각세포와의 공배양을 이용한 배아줄기세포의 내이 세포로의 분화 방법
JP7531808B2 (ja) * 2020-11-04 2024-08-13 国立大学法人 東京大学 騒音性難聴の予防剤
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1040908A (en) 1910-09-06 1912-10-08 George E Dunton Composition of matter for use in removing grease, &c., from the molds used in the art of electrotyping.
US1038708A (en) 1911-11-01 1912-09-17 Hipolit Zielinski Wrench.
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US4637402A (en) 1980-04-28 1987-01-20 Adelman Roger A Method for quantitatively measuring a hearing defect
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
ATE151617T1 (de) 1992-04-04 1997-05-15 Medical Res Council Prüfung des gehörs
ATE271614T1 (de) * 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
DE4402380A1 (de) 1994-01-27 1995-08-03 Hans Peter Prof Dr Med Zenner Implantierbares Dosiersystem
WO1998035658A2 (de) * 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon
ATE330592T1 (de) 1997-02-12 2006-07-15 Mse Pharmazeutika Gmbh Verwendung von 2,3-dimethoxy-5-methyl-6- decaprenyl-1,4-benzochinon in der behandlung von inkontinenz
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
AU2002216228A1 (en) * 2000-12-21 2002-07-01 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
WO2004093870A1 (en) 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
JP2008503579A (ja) 2004-06-21 2008-02-07 ハッチソン メディファーマ エンタープライジズ リミテッド 癌の化学療法
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070021497A1 (en) * 2005-07-11 2007-01-25 The Fruitful Yield Vitamin e compositions
CA2622523C (en) 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7786100B2 (en) * 2006-03-20 2010-08-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
WO2009061744A2 (en) * 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES

Also Published As

Publication number Publication date
CA2717741A1 (en) 2009-09-11
JP2015205938A (ja) 2015-11-19
EP2262519A4 (en) 2011-03-23
JP6131200B2 (ja) 2017-05-17
EP2262519A2 (en) 2010-12-22
WO2009111543A3 (en) 2009-12-30
US20110046156A1 (en) 2011-02-24
JP2017193590A (ja) 2017-10-26
WO2009111543A2 (en) 2009-09-11
US20180200248A1 (en) 2018-07-19
JP2014077019A (ja) 2014-05-01
JP2011513420A (ja) 2011-04-28
US20140249160A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
CA2717741C (en) Treatment of hearing and balance impairments with redox-active therapeutics
Kabir et al. NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer's therapy
US20230000881A1 (en) Methods and compositions for the prevention and treatment of hearing loss
JP3568039B2 (ja) アダマンタン誘導体の内耳炎治療向け使用
Campbell et al. Prevention of noise-and drug-induced hearing loss with D-methionine
Taleb et al. Hsp70 inhibits aminoglycoside-induced hearing loss and cochlear hair cell death
JP2022536017A (ja) 精神障害、行動障害、認知障害を処置する方法
Frankiewicz et al. Differential effects of NMDA–receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices
Zallocchi et al. Characterization of quinoxaline derivatives for protection against iatrogenically induced hearing loss
WO2001008705A1 (en) Remedies for neurogenic pains
KR102429935B1 (ko) 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
CN104244950B (zh) 含有西洛他唑及银杏叶提取物作为有效成分的听觉障碍预防或治疗用药物组合物
KR20210041755A (ko) 단백질 응집체 저해제
Gambôa et al. Amikacin ototoxicity: case report and literature review
WO2020235582A1 (ja) 運動ニューロン疾患の予防剤及び／又は治療剤
RU2224519C2 (ru) Антиоксидантное и стимулирующее рост нервных клеток средство
EP1471901B1 (en) Spermidine derivative for the treatment of chronic neurodegenerative diseases
JP2013014549A (ja) 抗癌剤の副作用軽減剤
KR20130020230A (ko) 네크록스를 유효성분으로 함유하는 난청의 예방 또는 치료용 약학 조성물
WO2004043447A2 (en) Compositions and methods for treating or preventing hearing impairment
HK40043809A (en) Methods and compositions for the prevention and treatment of hearing loss
EP3870159A1 (en) Drug for treating tinnitus
WO2019036581A1 (en) APPLICATION OF HONOKIOL IN ANTI-OTOTOXICITY AND HEARING PROTECTION
HK1249515B (zh) 预防和治疗听力损失的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140228

MKLA Lapsed

Effective date: 20210907

MKLA Lapsed

Effective date: 20200304